Amgen’s Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
This article was originally published in The Pink Sheet Daily
GAUSS-3 study shows role for Repatha as an alternative for patients with high cholesterol who can’t take statins, but real world impact may be minimal, due to pushback from payers – and even physicians.
You may also be interested in...
Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.
Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.